Rectal cancer treatment and outcome in the elderly: an audit based on the Swedish rectal cancer registry 1995–2004
© Jung et al; licensee BioMed Central Ltd. 2009
Received: 04 May 2008
Accepted: 26 February 2009
Published: 26 February 2009
Limited information is available regarding the effect of age on choice of surgical and oncological treatment for rectal cancer. The objective of this study was to assess the influence of age on treatment and outcome of rectal cancer.
We utilized data in the Swedish Rectal Cancer Registry (SRCR) from patients treated for rectal cancer in Sweden in 1995–2004.
A total of 15,104 patients with rectal cancer were identified, 42.4% of whom were 75 years or older. Patients ≥75 years were less likely to have distant metastases than younger patients (14.8% vs. 17.8%, P < 0.001), and underwent abdominal tumor resection less frequently (68.5% vs. 84.4%, P < 0.001). Of 11,725 patients with abdominal tumor resection (anterior resection [AR], abdominoperineal excision [APE], and Hartmann's procedure [HA]), 37.4% were ≥75 years. Curative surgery was registered for 85.0% of patients ≥ 75 years and for 83.9% of patients < 75 years, P = 0.11. Choice of abdominal operation differed significantly between the two age groups for both curative and non-curative surgery, The frequency of APE was similar in both age groups (29.5% vs. 28.6%), but patients ≥75 years were more likely to have HA (16.9% vs. 4.9%) and less likely to have preoperative radiotherapy (34.3vs. 67.2%, P < 0.001). The relative survival rate at five years for all patients treated with curative intent was 73% (70–75%) for patients ≥75 years and 78% (77–79%) for patients < 75 years of age. Local recurrence rate was 9% (8–11%) for older and 8% (7–9%) for younger patients.
Treatment of rectal cancer is influenced by patient's age. Future studies should include younger and older patients alike to reveal whether or not age-related differences are purposive. Local recurrence following surgery for low tumors and quality of life aspects deserve particular attention.
Rectal cancer predominantly affects persons over the age of 50. The annual number of rectal cancer cases diagnosed in Sweden has increased over the last twenty years, mainly due to the increasing age of the Swedish population, a trend that is expected to continue [1, 2]. Previous studies indicate that there is less inclination to perform surgery and adjuvant oncological treatment in elderly patients [3–5]. There is, however, mounting evidence that fit, elderly patients may benefit from surgery and adjuvant oncological treatment in much the same way as younger patients [6–8].
Since it began in 1995, the Swedish Rectal Cancer Registry (SRCR) has prospectively registered nearly 100% of patients diagnosed with rectal cancer in Sweden, along with data describing choice of surgical strategy, postoperative morbidity and mortality, neoadjuvant treatment, and long-term survival. The degree of coverage in the SRCR is 98–100% of patients with an adenocarcinoma of the rectum.
The aim of this audit was to investigate the influence in Sweden of age on choice of surgical strategy, use of preoperative radiotherapy, and outcome following abdominal surgery to treat rectal cancer.
All patients in the SRCR diagnosed from 1995 through 2004 were divided into two groups: ≥75 years and < 75 years of age at diagnosis. Abdominal tumor resection was defined as anterior resection (AR), abdominoperineal excision (APE), and Hartmann's procedure (HA). Cohorts used and outcomes (parentheses) analyzed are summarized below.
1995–2004: Patients with rectal cancer diagnosis, N = 15,104 (distant metastases [yes/no]). Abdominal tumor resection, N = 11,725 (tumor stage). Curative/noncurative surgery known, N = 11,510. Curative surgery N = 9,705 (tumor location, preoperative radiotherapy, reoperation at 30 days, relative survival 90 days following surgery, and relative 5-year survival).
Curative surgery was defined as a local radical procedure (R0) with tumor-negative resection margins in patients with no sign of distant metastases, according to UICC.
The study was approved by the Ethics Committee of the University of Umeå, Sweden (05-097M).
The chi-square test was used to test differences between proportions. Two-tailed P values < 0.05 were considered significant. SPSS v 13.0 (SPSS Inc, Chicago Illinois) software was used for statistical analyses. The statistical program Relsurv version 1.0  was utilised for analysis of relative survival, using data from the SRCR matched with data from The National Board of Health and Welfare's vital statistics [1, 2]. Local recurrence was calculated according to Kaplan-Meier with censoring of patients deceased before 31 December 2001 or with rectal cancer diagnosis after December 2001. This time was chosen as end point because all patients undergoing surgery for rectal cancer with curative intent are checked for local recurrence five years after surgery by Swedish Regional Oncologic Centres, and patients treated after December 2001 had not yet completed this control.
Data are presented as mean (95% confidence interval).
Tumor stage versus age and treatment
Between 1 January 1995 and 31 December 2004, 15,104 patients diagnosed with rectal cancer were identified in the SRCR. Of these, 42.4% were ≥75 years of age at diagnosis. The median age of patients ≥75 years was 80 years, and the median age was 65 years for those younger than 75 years. There was a lower proportion of men in the older group (54.1%) compared with the younger group (59.5%), P < 0.001. Among 6,407 patients ≥75 years (of total 15,104), 946 (14.8%) had distant metastases at diagnosis compared with 1,550 of 8,697 patients (17.8%) < 75 years of age, P < 0.001. Altogether, 11,725 of 15,104 patients (77.6%) had an abdominal tumor resection; 4,388 of 6,407 patients ≥75 years (68.5%), and 7,337 of 8,697 patients < 75 years (84.4%), P < 0.001.
Type of operation and tumor stage versus age of patients with abdominal tumor resection (N = 11,725)
< 75 years of age
≥ 75 years of age
N = 4,514
N = 2,235
Stage not known
N = 2181
N = 1,277
Stage not known
N = 642
N = 876
Stage not known
N = 7,337
N = 4,388
Stage not known
Choice of operation for curatively and noncuratively treated patients (N = 11,510).
< 75 years
≥ 75 years
N = 6,042
N = 3,663
N = 9,705
N = 1,160
N = 645
N = 1,805
Low tumors (0–6 cm from anal verge; N = 3445) versus type of operation and age in curatively treated patients (N = 9705).
< 75 years of age Low tumors (N = 2145)/curatively treated (N = 6042)
≥ 75 years of age Low tumors (N = 1114)/Curatively treated (N = 3663)
Use of preoperative radiotherapy versus surgical procedure and age in curatively treated patients (N = 9705).
< 75 years of age
N = 6,042
≥ 75 years of age
N = 3,663
P < 0.001
P < 0.001
P < 0.001
P < 0.001
As can be seen, older patients received preoperative radiotherapy less frequently than younger patients regardless of the surgical technique used, overall 34.3% versus 67.2%, for patients having curative surgery P < 0.001.
Reoperation within 30 days of curative surgery was performed in 340 of 3,663 patients (9.3%) ≥75 years and in 642 of 6,042 patients (10.3%) < 75 years, P = 0.036. The reoperation rate for each procedure did not, however, differ significantly between the age groups.
Relative survival 90 days postoperatively was slightly but significantly lower for older patients compared with younger patients following curative abdominal tumor resection: AR 96% (95–97%), mean (95% CI) vs. 99% (98.6–99.4%); APE 97% (96–98%) vs. 99% (98.5–99.5%); and HA 94% (92–96%) vs. 98%(96.7–100%). For all patients ≥75 years, relative survival 90 days following surgery was 96% (95–97%) compared with 99% (98.7–99.3%) for younger patients.
For all 15,104 patients registered in SRCR 1995–2004, the relative five-year survival was 62% (61–63%) for patients < 75 years vs. 52% (50–54%) for patients ≥75 years.
Local recurrrence rate
< 75 years
≥ 75 years
The main findings in this study can be summarized as follows: Among patients 75 years or older, distant metastases were diagnosed less frequently than in younger patients. Older patients underwent abdominal surgery less frequently but they had more HA:s than younger patients. Preoperative radiotherapy was used for 34% of patients ≥75 years, compared with 67% of younger patients. Older patients had lower relative survival 90 days postoperatively and lower relative five-year survival among all patients, among patients with abdominal tumor resection, and among patients with curative operation. Local recurrence rate did not, however, differ significantly between the two age groups.
The SRCR covers nearly 100% of rectal cancer patients in Sweden, providing an adequate description of the management of rectal cancer in a defined population. It has the possibility to use person-numbers, unique for each resident in Sweden. The register is validated and the quality of data has been shown to be acceptable. This makes descriptive data from this register of interest when planning studies validating future treatment programs for rectal cancer. The SRCR is nationwide and therefore the data input is limited to ensure acceptable registration compliance. American Association of Anesthesiologists (ASA) classification has been added to the registry in 2007. This information could have been helpful in trying to understand some of the results of our study, since older patients are expected to have more comorbidity, as shown in previous studies [11–13].
Local recurrence rate in our audit was calculated using a cohort different from the main cohort. The reason for this is the method of gathering information about local recurrence from colorectal units to Regional Oncologic Centres yearly, asking for local recurrence data for every patient five years post year of surgery.
The choice of surgical strategy for tumors more than 6 cm from the anal verge differed substantially between the older and younger age groups. HA was chosen more often for older patients with less advanced disease, which does not concur with a previous report, where sphincter saving surgery was used in the majority of patients in both age groups. This is the most likely explanation for the tendency towards a better five-year relative survival rate in older patients compared with younger patients treated with HA in our audit. The preference for HA in elderly patients in our audit, as well as in a study from Norway, could be due to concern about the functional result (risk for fecal incontinence) after restorative surgery in older patients. There is some evidence that the functional result after AR is acceptable in older patients, and chronological age alone should not exclude patients from restorative surgery for rectal cancer. However, available studies comparing quality of life in patients treated for rectal cancer with a permanent stoma (HA) and restorative surgery (AR) do not demonstrate a significant difference between the two alternatives [16, 17]. Further prospective studies in this aspect are important, since the short-term and long-term survival did not differ significantly between patients in the AR and HA groups in our audit.
A slightly lower relative survival at 90 days for elderly patients highlights the physiological age limit for major abdominal surgery. Although the reoperation rate differed very little between the age groups, one may anticipate that reoperation imposes a greater risk in elderly patients compared with younger patients. Older patients who underwent abdominal tumor resection had a less favorable relative five-year survival than younger patients (64% vs. 68%), in spite of less advanced tumor stage (10.3 vs 13.4 stage IV). The five-year relative survival was also lower for older patients than for younger patients treated with curative intent. It is of special interest that preoperative radiotherapy prior to APE was used in 47% of patients ≥ 75 years, compared with 82% in younger patients. However, no significant difference in the five-year local recurrence rate after APE was seen. This indicates that preoperative radiotherapy alone cannot entirely explain the slightly worse five-year relative survival in older patients.
The total mesorectal excision technique (TME) [18–22] was introduced in Sweden during the latter half of the 1990s after initial studies. A similar introduction took place during the same period in Norway[17, 24]. The impact of the TME technique in reducing the local recurrence rate is evident from population-based educational programs[22, 24]. There is ongoing discussion regarding the need for improvement in APE surgical techniques for better local control in order to improve outcome and possibly to reduce the need for preoperative radiotherapy[9, 25]. Population-based studies with prospective detailed registration of surgical technique may shed light on this important issue.
The extent to which preoperative radiotherapy should be used in rectal cancer treatment is controversial. Preoperative radiotherapy is known to improve local control but it also increases the probability of fecal incontinence, sexual dysfunction, and late hospital admission [26–31]. Negative side effects have been more pronounced in older patients, as was shown in the Stockholm I and II trials[32, 33]. This is probably one factor explaining the low rate of preoperative radiotherapy in the older age group in our audit. However, it should be noted that modern radiotherapy has a higher tolerability than techniques used in previous trials. Further studies, preferably with a cost-benefit approach, concerning preoperative radiotherapy are needed.
A higher threshold for resectional surgery was seen in elderly patients, who were less likely to have stage IV disease at operation. This age-dependent difference in tumor stage was identified in all operations. It was most pronounced for HA, frequently used in elderly patients. Five-year relative survival was lower for all elderly patients and for elderly patients treated with curative intent, whereas local recurrence rate was comparable in the two age groups. In order to improve outcomes for patients with rectal cancer both population-based studies and trials comprising older and younger patients, with emphasis on physiological and quality-of-life aspects, are needed.
The authors thank the Lion's Cancer Research Foundation at the University of Umeå for funding this project. We also thank all Swedish colorectal surgeons for prospectively collecting data on treatment of rectal cancer patients. Their effort was a prerequisite for the present study. This work was supported by the Swedish Cancer Society, project number 1921-B03-21XCC. SRCR is funded by The Swedish Association of Local Authorities and Regions (SALAR).
- National board of Health and Welfare S: [http://www.socialstyrelsen.se/Statistik/statistik_amne/index.htm]
- Statistics Sweden: [http://www.scb.se]
- Newcomb PA, Carbone PP: Cancer Treatment and Age: Patient Perspectives. J Natl Cancer Inst. 1993, 85 (19): 1580-1584. 10.1093/jnci/85.19.1580.View ArticlePubMedGoogle Scholar
- Mor V, Masterson-Allen S, Goldberg RJ, Cummings FJ, Glicksman AS, Fretwell MD: Relationship between age at diagnosis and treatments received by cancer patients. J Am Geriatr Soc. 1985, 33 (9): 585-589.View ArticlePubMedGoogle Scholar
- Cohen SM, Neugut AI: Adjuvant therapy for rectal cancer in the elderly. Drugs Aging. 2004, 21 (7): 437-451. 10.2165/00002512-200421070-00003.View ArticlePubMedGoogle Scholar
- Avital S, Kashtan H, Hadad R, Werbin N: Survival of colorectal carcinoma in the elderly. A prospective study of colorectal carcinoma and a five-year follow-up. Dis Colon Rectum. 1997, 40 (5): 523-529. 10.1007/BF02055371.View ArticlePubMedGoogle Scholar
- Kiran RP, Pokala N, Dudrick SJ: Long-term outcome after operative intervention for rectal cancer in patients aged over 80 years: analysis of 9,501 patients. Dis Colon Rectum. 2007, 50 (5): 604-610. 10.1007/s10350-006-0802-0.View ArticlePubMedGoogle Scholar
- Puig-La Calle J, Quayle J, Thaler HT, Shi W, Paty PB, Quan SH, Cohen AM, Guillem JG: Favorable short-term and long-term outcome after elective radical rectal cancer resection in patients 75 years of age or older. Dis Colon Rectum. 2000, 43 (12): 1704-1709. 10.1007/BF02236854.View ArticlePubMedGoogle Scholar
- Pahlman L, Bohe M, Cedermark B, Dahlberg M, Lindmark G, Sjodahl R, Ojerskog B, Damber L, Johansson R: The Swedish rectal cancer registry. Br J Surg. 2007, 94 (10): 1285-1292. 10.1002/bjs.5679.View ArticlePubMedGoogle Scholar
- Hakulinen T, Abeywickrama KH: A computer program package for relative survival analysis. Comput Programs Biomed. 1985, 19 (2–3): 197-207. 10.1016/0010-468X(85)90011-X.View ArticlePubMedGoogle Scholar
- Lemmens VE, Janssen-Heijnen ML, Verheij CD, Houterman S, Repelaer van Driel OJ, Coebergh JW: Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg. 2005, 92 (5): 615-623. 10.1002/bjs.4913.View ArticlePubMedGoogle Scholar
- Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW: Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol. 2005, 55 (3): 231-240. 10.1016/j.critrevonc.2005.04.008.View ArticlePubMedGoogle Scholar
- Shahir MA, Lemmens VE, Poll-Franse van de LV, Voogd AC, Martijn H, Janssen-Heijnen ML: Elderly patients with rectal cancer have a higher risk of treatment-related complications and a poorer prognosis than younger patients: A population-based study. Eur J Cancer. 2006Google Scholar
- Endreseth BH, Romundstad P, Myrvold HE, Bjerkeset T, Wibe A: Rectal cancer treatment of the elderly. Colorectal Dis. 2006, 8 (6): 471-479. 10.1111/j.1463-1318.2005.00921.x.View ArticlePubMedGoogle Scholar
- Phillips PS, Farquharson SM, Sexton R, Heald RJ, Moran BJ: Rectal cancer in the elderly: patients' perception of bowel control after restorative surgery. Dis Colon Rectum. 2004, 47 (3): 287-290. 10.1007/s10350-003-0051-4.View ArticlePubMedGoogle Scholar
- Pachler J, Wille-Jorgensen P: Quality of life after rectal resection for cancer, with or without permanent colostomy. Cochrane Database Syst Rev. 2005, CD004323-2Google Scholar
- Guren MG, Eriksen MT, Wiig JN, Carlsen E, Nesbakken A, Sigurdsson HK, Wibe A, Tveit KM: Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer. Eur J Surg Oncol. 2005, 31 (7): 735-742. 10.1016/j.ejso.2005.05.004.View ArticlePubMedGoogle Scholar
- Heald RJ: The 'Holy Plane' of rectal surgery. J R Soc Med. 1988, 81 (9): 503-508.PubMedPubMed CentralGoogle Scholar
- Arbman G, Nilsson E, Hallbook O, Sjodahl R: Local recurrence following total mesorectal excision for rectal cancer. Br J Surg. 1996, 83 (3): 375-379. 10.1002/bjs.1800830326.View ArticlePubMedGoogle Scholar
- Dahlberg M, Pahlman L, Bergstrom R, Glimelius B: Improved survival in patients with rectal cancer: a population-based register study. Br J Surg. 1998, 85 (4): 515-520. 10.1046/j.1365-2168.1998.00603.x.View ArticlePubMedGoogle Scholar
- Dahlberg M, Glimelius B, Pahlman L: Changing strategy for rectal cancer is associated with improved outcome. Br J Surg. 1999, 86 (3): 379-384. 10.1046/j.1365-2168.1999.01040.x.View ArticlePubMedGoogle Scholar
- Martling A, Holm T, Rutqvist LE, Johansson H, Moran BJ, Heald RJ, Cedermark B: Impact of a surgical training programme on rectal cancer outcomes in Stockholm. Br J Surg. 2005, 92 (2): 225-229. 10.1002/bjs.4834.View ArticlePubMedGoogle Scholar
- Arbman G, Nilsson E, Storgren-Fordell V, Sjodahl R: Outcome of surgery for colorectal cancer in a defined population in Sweden from 1984 to 1986. Dis Colon Rectum. 1995, 38 (6): 645-650. 10.1007/BF02054127.View ArticlePubMedGoogle Scholar
- Wibe A, Carlsen E, Dahl O, Tveit KM, Weedon-Fekjaer H, Hestvik UE, Wiig JN: Nationwide quality assurance of rectal cancer treatment. Colorectal Disease. 2006, 8 (3): 224-229. 10.1111/j.1463-1318.2005.00924.x.View ArticlePubMedGoogle Scholar
- Holm T, Ljung A, Haggmark T, Jurell G, Lagergren J: Extended abdominoperineal resection with gluteus maximus flap reconstruction of the pelvic floor for rectal cancer. Br J Surg. 2007, 94 (2): 232-238. 10.1002/bjs.5489.View ArticlePubMedGoogle Scholar
- Lange MM, den Dulk M, Bossema ER, Maas CP, Peeters KC, Rutten HJ, Klein Kranenbarg E, Marijnen CA, Velde van de CJ: Risk factors for faecal incontinence after rectal cancer treatment. Br J Surg. 2007, 94 (10): 1278-1284. 10.1002/bjs.5819.View ArticlePubMedGoogle Scholar
- Swedish Rectal Cancer T: Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer. N Engl J Med. 1997, 336 (14): 980-987. 10.1056/NEJM199704033361402.View ArticleGoogle Scholar
- Kapiteijn E, Kranenbarg EK, Steup WH, Taat CW, Rutten HJ, Wiggers T, van Krieken JH, Hermans J, Leer JW, Velde van de CJ: Total mesorectal excision (TME) with or without preoperative radiotherapy in the treatment of primary rectal cancer. Prospective randomised trial with standard operative and histopathological techniques. Dutch ColoRectal Cancer Group. Eur J Surg. 1999, 165 (5): 410-420. 10.1080/110241599750006613.View ArticlePubMedGoogle Scholar
- Dahlberg M, Glimelius B, Graf W, Pahlman L: Preoperative irradiation affects functional results after surgery for rectal cancer: results from a randomized study. Dis Colon Rectum. 1998, 41 (5): 543-549. 10.1007/BF02235256. discussion 549–551View ArticlePubMedGoogle Scholar
- Birgisson H, Pahlman L, Gunnarsson U, Glimelius B: Adverse Effects of Preoperative Radiation Therapy for Rectal Cancer: Long-Term Follow-Up of the Swedish Rectal Cancer Trial. J Clin Oncol. 2005, 23 (34): 8697-8705. 10.1200/JCO.2005.02.9017.View ArticlePubMedGoogle Scholar
- Birgisson H, Pahlman L, Gunnarsson U, Glimelius B: Late adverse effects of radiation therapy for rectal cancer – a systematic overview. Acta Oncol. 2007, 46 (4): 504-516. 10.1080/02841860701348670.View ArticlePubMedGoogle Scholar
- Holm T, Rutqvist LE, Johansson H, Cedermark B: Postoperative mortality in rectal cancer treated with or without preoperative radiotherapy: causes and risk factors. Br J Surg. 1996, 83 (7): 964-968. 10.1002/bjs.1800830725.View ArticlePubMedGoogle Scholar
- Holm T, Singnomklao T, Rutqvist LE, Cedermark B: Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow-up of two randomized trials. Cancer. 1996, 78 (5): 968-976. 10.1002/(SICI)1097-0142(19960901)78:5<968::AID-CNCR5>3.0.CO;2-8.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/68/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.